

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850 UNITED STATES Phone: +1-888-267-4436 Fax: +1-301-340-8606

techsupport@origene.com

OriGene Technologies GmbH

Schillerstr. 5 32052 Herford **GERMANY** Phone: +49-5221-34606-0

Fax: +49-5221-34606-11 info-de@origene.com

SM1847LE Monoclonal Antibody to CD253 / TRAIL (95-281) - Low Endotoxin

Alternate names: APO2L, Apo-2 ligand, Apo-2L, TNF-related apoptosis-inducing ligand, TNFSF10, Tumor

necrosis factor ligand superfamily member 10

Quantity: 0.1 mg **Concentration:** 1.0 mg/ml

Background: Human CD253 / TRAIL (TNF-Related Apoptosis Inducing Ligand), also called Apo2, is a

> type II membrane protein from the TNF family. TRAIL is a cytotoxic protein which activates rapid apoptosis in tumor cells, but not in normal cells. TRAIL-induced apotosis, is achieved through binding to two dealth-signaling receptors, DR4 (CD261/

TRAIL-R1) and DR5 (CD262 / TRAIL-R2).

Uniprot ID: P50591

NCBI: NP 003801.1

GeneID: 8743

Host / Isotype: Mouse / IgG1

Recommended Isotype

Controls:

SM10LE (for use in human samples)

Clone: 2E5

Immunogen: Recombinant soluble fragment (aa 95-281) of human TRAIL

Format: State: Liquid Ig fraction

Purification: Protein A (> 95% pure by SDS-PAGE)

Buffer System: Buffered saline (PBS), approx. pH 7.4; 0.2 µm filter sterilized Endotoxin Level: Less than 0.01 EU/µg of the protein, as determined by the LAL test

Applications: Functional application: High neutralizing activity for human TRAIL in biological

assays.

Flow cytometry: 1-10 µg/ml.

Other applications not tested. Optimal dilutions are dependent on conditions and

should be determined by the user.

This antibody reacts with TRAIL (APO-2L), a 21 kDa cytotoxic protein, activator of rapid **Specificity:**

apoptosis in tumor cells. TRAIL is mainly expressed in spleen, lung, prostate and also

in many other tissues.

Species Reactivity: Tested: Human. Does not work in Mouse.

Store undiluted at 2-8°C. Storage:

DO NOT FREEZE!

Shelf life: one year from despatch.

General Readings: 1. Plasilova M, Zivny J, Jelinek J, Neuwirtova R, Cermak J, Necas E, et al. TRAIL (Apo2L)

suppresses growth of primary human leukemia and myelodysplasia progenitors.

Leukemia. 2002 Jan;16(1):67-73. PubMed PMID: 11840265.

2. Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, Lu M, et al. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand



to induce apoptosis of breast cancer cells. Cancer Res. 2005 Jun 1;65(11):4799-808. PubMed PMID: 15930300.

Pictures:

Apoptosis induced in JURKAT human T cell leukemia cell line by soluble recombinant human TRAIL is completely blocked by anti-human TRAIL (2E5). The neutralizing activity of the antibody 2E5 has been confirmed with various sources of soluble recombinant human TRAIL.

A - medium

B - recombinant TRAIL

C - recombinant TRAIL + anti-human

TRAIL (2E5; $0.06 \mu g/ml$)

D - recombinant TRAIL + anti-human

TRAIL (2E5; $0.24 \mu g/ml$)

E - recombinant TRAIL + Isotype mouse IgG1 controlE - recombinant TRAIL + Isotype mouse IgG1 control

